(Q42279908)

English

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial

scientific article published on 7 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 October 2017

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trial (English)

1 reference

Europe PubMed Central

19 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lopinavir/ritonavir

1 reference

based on heuristic

inferred from title

atazanavir/ritonavir

1 reference

based on heuristic

inferred from title

Staffan Nilsson

5

object named as

Staffan Nilsson

1 reference

Europe PubMed Central

19 October 2017

Anders Blaxhult

3

object named as

Anders Blaxhult

1 reference

Europe PubMed Central

19 October 2017

Magnus Gisslén

8

object named as

Magnus Gisslén

1 reference

Europe PubMed Central

19 October 2017

4

object named as

Leo Flamholc

1 reference

Europe PubMed Central

19 October 2017

author name string

Lars-Magnus Andersson

1

1 reference

Europe PubMed Central

19 October 2017

Jan Vesterbacka

2

1 reference

Europe PubMed Central

19 October 2017

Vidar Ormaasen

6

1 reference

Europe PubMed Central

19 October 2017

Anders Sönnerborg

7

1 reference

Europe PubMed Central

19 October 2017

publication date

7 January 2013

1 reference

Europe PubMed Central

19 October 2017

Scandinavian Journal of Infectious Diseases

1 reference

Europe PubMed Central

19 October 2017

45

1 reference

Europe PubMed Central

19 October 2017

7

1 reference

Europe PubMed Central

19 October 2017

543-551

1 reference

Europe PubMed Central

19 October 2017

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE.

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010

1 reference

https://api.crossref.org/works/10.3109%2F00365548.2012.756985

21 January 2018

Identifiers

10.3109/00365548.2012.756985

1 reference

Europe PubMed Central

19 October 2017

1 reference

Europe PubMed Central

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42279908&oldid=1940971480"